Ignite Creation Date:
2025-12-25 @ 2:55 AM
Ignite Modification Date:
2025-12-26 @ 1:36 AM
Study NCT ID:
NCT06158633
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-06
First Post:
2023-10-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults
Sponsor:
CHX Technologies Inc.
Organization:
Study Overview
Official Title:
A Pilot, Observation and Feasibility Study of Prevora (DIN 02046245) Integrated Into Homecare Visits of Adults With COPD or CHF or on Dialysis or Other Chronic Metabolic Conditions Which Are Correlated With Chronic Oral Inflammation
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prevora is an antiseptic medication and dental treatment approved by Health Canada for reducing root decay (cavities) in adults at high risk of dental decay. An antiseptic kills germs and harmful bacteria. Prevora is applied to the teeth and gumline by a medical professional, takes about 10 minutes and is painless.
Participating site(s) have a homecare program and usual care includes offering patients home care services before discharge from the hospital for some chronic diseases. Usual care includes home visits by a nurse and or personal support worker (PSW).
The aim of this study is to explore the effectiveness, health benefits and feasibility of delivering preventive oral healthcare with Prevora, during a homecare visit by a nurse or PSW. All consenting and eligible subjects will continue with their usual care with the homecare program. The study is 5 months long. Subjects will have a Prevora treatment applied by the homecare nurse or PSW on Day 1, 14 days, 3 months and 4 months. The study includes several follow up visits which will be conducted in the patient's home and or by telephone or videoconferencing if needed. Oral exams, lab tests and subject completed questionnaires will be collected for the study. Changes in medications and any possible side effects will also be monitored during the study.
Participating site(s) have a homecare program and usual care includes offering patients home care services before discharge from the hospital for some chronic diseases. Usual care includes home visits by a nurse and or personal support worker (PSW).
The aim of this study is to explore the effectiveness, health benefits and feasibility of delivering preventive oral healthcare with Prevora, during a homecare visit by a nurse or PSW. All consenting and eligible subjects will continue with their usual care with the homecare program. The study is 5 months long. Subjects will have a Prevora treatment applied by the homecare nurse or PSW on Day 1, 14 days, 3 months and 4 months. The study includes several follow up visits which will be conducted in the patient's home and or by telephone or videoconferencing if needed. Oral exams, lab tests and subject completed questionnaires will be collected for the study. Changes in medications and any possible side effects will also be monitored during the study.
Detailed Description:
Poor oral health and specifically, inflammation of the gums is linked to respiratory problems, heart problems and inflammation through the body. Worsening oral health and inflammation of the gums occurs often in patients with chronic diseases who are hospitalized and often continues after discharge from the hospital. This can make health recovery more difficult for the patient.
This is a 5 month, prospective, single-arm, open-label, observational and feasibility, phase IV trial evaluating the efficacy and safety of Prevora and is focused on the integration of a preventive oral healthcare service into a hospital-based home healthcare program involving high-risk adults with COPD or CHF or on dialysis, and possibly other chronic metabolic conditions, which make the patient suitable for entry into a home care program. This study will be centrally coordinated by the Research Institute at St Joes and conducted in the homes of consenting and eligible participants in the greater Hamilton, Ontario area.
Approximately 30 subjects will be enrolled in the study which is defined as starting the investigational product. All subjects will continue to receive the usual care that is provided as part of the respective home care program. After signed consent is obtained, subject screening and eligibility assessments will begin. Once a subject is confirmed to be eligible for study participation, investigational product treatment applications and study visits will be scheduled starting with Day 1.
Follow up visits will occur 14 days, 1, 3, 4 and 5 months after Day 1. A delegated and trained homecare nurse or PSW will apply the investigational product during the study visits conducted on day 1, day 14, 3 and 4 months. Study visits will be scheduled at the same time as a standard of care (SOC) home visit or as a study visit only, independent of a SOC home visit. Study visits include evaluation of study outcomes/endpoints, subject completed questionnaires and measuring compliance. Changes in medications and any possible side effects will also be monitored during the study. Data will be captured in the case report form (CRF).
To qualify, men and women must be enrolled in the home healthcare services program. All participants will receive the study intervention (Prevora) and be followed for 5 months.
This study aims to demonstrate that in subjects who receive home healthcare visits and have COPD and/or CHF or on dialysis, and with moderate to severe forms of chronic oral inflammation, the investigational product (Prevora) will significantly decrease oral inflammation over time.
This is a 5 month, prospective, single-arm, open-label, observational and feasibility, phase IV trial evaluating the efficacy and safety of Prevora and is focused on the integration of a preventive oral healthcare service into a hospital-based home healthcare program involving high-risk adults with COPD or CHF or on dialysis, and possibly other chronic metabolic conditions, which make the patient suitable for entry into a home care program. This study will be centrally coordinated by the Research Institute at St Joes and conducted in the homes of consenting and eligible participants in the greater Hamilton, Ontario area.
Approximately 30 subjects will be enrolled in the study which is defined as starting the investigational product. All subjects will continue to receive the usual care that is provided as part of the respective home care program. After signed consent is obtained, subject screening and eligibility assessments will begin. Once a subject is confirmed to be eligible for study participation, investigational product treatment applications and study visits will be scheduled starting with Day 1.
Follow up visits will occur 14 days, 1, 3, 4 and 5 months after Day 1. A delegated and trained homecare nurse or PSW will apply the investigational product during the study visits conducted on day 1, day 14, 3 and 4 months. Study visits will be scheduled at the same time as a standard of care (SOC) home visit or as a study visit only, independent of a SOC home visit. Study visits include evaluation of study outcomes/endpoints, subject completed questionnaires and measuring compliance. Changes in medications and any possible side effects will also be monitored during the study. Data will be captured in the case report form (CRF).
To qualify, men and women must be enrolled in the home healthcare services program. All participants will receive the study intervention (Prevora) and be followed for 5 months.
This study aims to demonstrate that in subjects who receive home healthcare visits and have COPD and/or CHF or on dialysis, and with moderate to severe forms of chronic oral inflammation, the investigational product (Prevora) will significantly decrease oral inflammation over time.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: